Bacil Pharma Ltd
Bacil Pharma Limited is a Mumbai-registered listed company incorporated in 1987. Although its stated business is pharmaceutical healthcare, it recorded no core operating revenue in FY26 and is currently an investment/other-income-led, non-operating company evaluating future business opportunities.[1] [2]
- Market Cap ₹ 27.4 Cr.
- Current Price ₹ 19.1
- High / Low ₹ 61.8 / 10.6
- Stock P/E 17.6
- Book Value ₹ 17.6
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.09 times its book value
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| 0.00 | |
| 0.25 | |
| Operating Profit | -0.25 |
| OPM % | |
| 1.24 | |
| Interest | 0.00 |
| Depreciation | 0.00 |
| Profit before tax | 0.99 |
| Tax % | -57.58% |
| 1.56 | |
| EPS in Rs | 1.09 |
| Dividend Payout % | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 18% |
| 3 Years: | 30% |
| 1 Year: | -52% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Equity Capital | |
| Reserves | |
| Total Liabilities | |
| CWIP | |
| Investments | |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| 1.71 | |
| -3.38 | |
| -0.62 | |
| Net Cash Flow | -2.29 |
| Free Cash Flow | 1.71 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -684% |
Ratios
Consolidated / View Standalone
| Mar 2026 | |
|---|---|
| Debtor Days | |
| Inventory Days | |
| Days Payable | |
| Cash Conversion Cycle | |
| Working Capital Days | |
| ROCE % |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Loans and Advances given (Non-Current) INR Lakhs ・Standalone data |
|
||||||||||
| Total Investments Held (Non-Current + Current) INR Lakhs ・Standalone data |
|||||||||||
| Number of Permanent Employees count ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Un-Audited Financial Result For The Quarter And Half Yearly Ended 30Th September, 2026
- Board approved unaudited standalone and consolidated results for quarter and half year ended 30 September 2026.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 14Th October, 2026
- Board approved standalone and consolidated unaudited results for quarter and half year ended 30 September 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Submitted Regulation 74(5) certificate for quarter ended 30 September 2026.
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
- Whole-Time Company Secretary Dikshant Singh Panwar resigned effective 08 October 2026; replacement process underway.
-
Board Meeting Intimation for We Wish To Inform That The Meeting Of The Board Of The Company Is Scheduled To Be Held On Wednesday, 14Th October, 2026
- Board meeting on 14 Oct 2026 to approve unaudited results for half-year and quarter ended 30 Sep 2026.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Operational Status:
The Co. develops, manufactures, and distributes specialty pharmaceutical products, including tablets, capsules, injectables, and ointments across various therapeutic segments. Despite its product range, the company generated nil revenue from operations in FY26.[1] [2]